Portable communications device integrating remote control of rail track switches and movement of a locomotive in a train yard

Details for Australian Patent Application No. 2004213455 (hide)

Owner General Electric Company

Inventors Kornick, David; Foy, Robert James

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2004213455

PCT Pub. Number WO2004/074068

Priority 10/759,319 16.01.04 US; 60/448,701 20.02.03 US; 60/528,862 11.12.03 US

Filing date 20 February 2004

Wipo publication date 2 September 2004

Acceptance publication date 19 November 2009

International Classifications

B61L 3/12 (2006.01) Devices along the route for controlling devices on the vehicle or vehicle train, e.g. to release brake, to operate a warning signal

B61L 7/06 (2006.01) Remote control of local operating means for points, signals, or track-mounted scotch-blocks

B61L 17/00 (2006.01) Switching systems for classification yards

Event Publications

29 September 2005 PCT application entered the National Phase

  PCT publication WO2004/074068 Priority application(s): WO2004/074068

29 October 2009 Amendment Made

  The nature of the amendment is: Amend the invention title to read Portable communications device integrating remote control of rail track switches and movement of a locomotive in a train yard

19 November 2009 Application Accepted

  Published as AU-B-2004213455

18 March 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004213458-Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino- ]-7-methyl-1H-benzimidazole-4-carbonit rile and its preferred salt form

2004213452-Novel therapeutic GPCRr targets in cancer